And on Jan. 7, Ribozyme formed a joint venture with Elan to develop Ribozyme's Herzyme for the treatment of breast cancer. More This isn't the only biotechnology portfolio that an investor can build, of course. No knock on these companies or their technology. But I also know the history of the biotechnology sector. To say it's volatile is a classic understatement.
Prices seem to move to extremes overnight and then correct with violence.
There's nothing wrong about being conservative when you invest in a sector like this. With the Fed meeting set for March 21, I'm going to sell now so that I don't get caught with less cash than I want in any decline as the date approaches. IBM remains in my Future 50 portfolio for investors with a five-year or longer time horizon. I think the stock has farther to go as investors get increasingly comfortable with the company's strategy and plans for the Internet hosting business. Icos, Isis, Ligand, Microcide, Vertex and Vical.